Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part IV. Patient Important Outcomes.
Rotz SJ, Wiener L, Baker KS, Choi SW, Phelan R, Cuvelier GDE, Duncan C, Williams KM, Qayed M. Rotz SJ, et al. Among authors: qayed m. Transplant Cell Ther. 2024 Dec 27:S2666-6367(24)00838-8. doi: 10.1016/j.jtct.2024.12.019. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39733839
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.
Katsivelos N, Spyrou N, Weber D, Vasova I, Ayuk F, Choe H, Hogan W, DeFilipp Z, Qayed M, Etra AM, Sandhu K, Kraus S, Olson T, Hexner E, Aguayo-Hiraldo P, Reshef R, Ullrich E, Schechter T, Kitko C, Chanswangphuwana C, Merli P, Akahoshi Y, Baez J, Eng G, Beheshti R, Kowalyk S, Morales G, Louloudis IE, Young R, Holler E, Nakamura R, Ferrara JLM, Levine JE. Katsivelos N, et al. Among authors: qayed m. Transplant Cell Ther. 2024 Nov 26:S2666-6367(24)00730-9. doi: 10.1016/j.jtct.2024.10.012. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39667999
Why are Higher CD34+ Cell Doses Associated with Improved Outcomes among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors - But Not for High-Risk Neuroblastoma?
Knight TE, Broglie L, Sharma A, Qayed M, Yanik GA. Knight TE, et al. Among authors: qayed m. Pediatr Hematol Oncol. 2024 Nov 5:1-5. doi: 10.1080/08880018.2024.2420924. Online ahead of print. Pediatr Hematol Oncol. 2024. PMID: 39501613 No abstract available.
Ibrutinib for therapy of steroid-refractory chronic graft vs. host disease: A multicenter real-world analysis.
Pidala JA, Kim J, Kalos D, Cutler CS, DeFilipp Z, Flowers ME, Hamilton BK, Chin KK, Rotta M, El Jurdi N, Hamadani M, Ahmed G, Kitko CL, Ponce DM, Sung AD, Tang H, Farhadfar N, Nemecek ER, Pusic I, Qayed M, Rangarajan HG, Hogan WJ, Etra AM, Jaglowski SM. Pidala JA, et al. Among authors: qayed m. Blood Adv. 2024 Oct 25:bloodadvances.2024014374. doi: 10.1182/bloodadvances.2024014374. Online ahead of print. Blood Adv. 2024. PMID: 39454280
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.
Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermúdez A, Kim I, Socié G, Chhabra S, Radojcic V, O'Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL; AGAVE-201 Investigators. Wolff D, et al. N Engl J Med. 2024 Sep 19;391(11):1002-1014. doi: 10.1056/NEJMoa2401537. N Engl J Med. 2024. PMID: 39292927 Clinical Trial.
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.
Rios CAO, Qayed M, Etra AM, Reshef R, Newcomb R, Yuhasz N, Hexner EO, Aguayo-Hiraldo P, Merli P, Hogan WJ, Weber D, Kitko CL, Ayuk F, Eder M, Grupp SA, Kraus S, Sandhu K, Ullrich E, Vasova I, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Louloudis IE, Morales G, Spyrou N, Young R, Nakamura R, Levine JE, Ferrara JLM, Akahoshi Y. Rios CAO, et al. Among authors: qayed m. Transplant Cell Ther. 2024 Nov;30(11):1061.e1-1061.e10. doi: 10.1016/j.jtct.2024.08.019. Epub 2024 Sep 1. Transplant Cell Ther. 2024. PMID: 39222793
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.
Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Morales G, Young R, Chen YB, Nakamura R, Levine JE, Ferrara JLM. Akahoshi Y, et al. Among authors: qayed m. Blood. 2024 Aug 29;144(9):1010-1021. doi: 10.1182/blood.2024025106. Blood. 2024. PMID: 38968143
Real-World Application of Recently Proposed ASTCT/CIBMTR/EBMT/APBMT Consensus Risk Stratification for Transplantation-Associated Thrombotic Microangiopathy in Children.
Schoettler ML, Ofori J, Bryson E, Spencer K, Qayed M, Stenger E, Bidgoli A, Chonat S, Westbrook A, Williams KM. Schoettler ML, et al. Among authors: qayed m. Transplant Cell Ther. 2024 Sep;30(9):929.e1-929.e6. doi: 10.1016/j.jtct.2024.06.017. Epub 2024 Jun 25. Transplant Cell Ther. 2024. PMID: 38936547
124 results